Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPESC-RPE-4W cell therapy in dry AMD
NCT04627428Phase 2Recruiting
- Sponsor
- Luxa Biotechnology
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of RPESC-RPE-4W in age-related macular degeneration (AMD), sponsored by Luxa Biotechnology. Started Apr 2022; status: recruiting.
02
Drugs
RPESC-RPE-4W
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT04627428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627428.